Are you confident in your understanding of the different clinical phenotypes and presentations of late-onset genetic cholestasis? Watch this 5-minute animation to learn more about the pathophysiology and genetics behind the disease. Watch here

RT @SpringerNature: To enable researchers to publish their research open access, Springer Nature has expanded its transformative agreements…

Stay up to date with the latest advancements in Primary Biliary Cholangitis (PBC). Dive into our comprehensive, downloadable summary of key trial data from the AASLD 2024 Liver Meeting. Download the FREE summary here: Website

RT @NatRevBiodiv: Here we go! The first issue of Nature Reviews Biodiversity is now live🥳🎉🥂. Thank you to our authors, reviewers, and comm…

Are you looking to stay up to date with the latest advancements in Primary Biliary Cholangitis (PBC)? Dive into our comprehensive, downloadable summary of key trial data from the AASLD 2024 Liver Meeting. Download the FREE summary here:

Stay up to date with the latest developments in late-onset genetic cholestasis with curated content from the American Association for the Study of Liver Diseases (AASLD) 'The Liver Meeting' Access all content here #AASLD #AASLD24 #TheLiverMeeting

Empower your patients with NSCLC through Shared Decision-Making. These tools, developed in collaboration with patients, will help you engage in meaningful conversations about biomarker testing and targeted therapies. Download the tools for free #NSCLC

Access the highlights from #CTAD24. Throughout the congress, we provided daily coverage packed with valuable insights, including plenty of news nuggets and breakfast bites that spotlight the latest advancements in Alzheimer’s research. #Alzheimers

Watch our interview with Claire Paquet as she discusses her thoughts on the real-world findings for lecanemab and the appropriate use recommendations for donanemab presented at #CTAD24

RT @SpringerNature: We are excited to share that Nature Navigator, Springer Nature’s AI powered tool to help research decision makers track…

#CTAD24: Does a preference for off-target binding of vascular amyloid-β explain differences in ARIA-E rates among anti-amyloid monoclonal antibody treatments? Read the news story here

#CTAD24 Watch our interview with Juan Fortea (@HospitalSantPau) as he discusses his hopes for future opportunities with amyloid-targeting therapy in AD

ADNI cohort analysis suggests need for further evidence of disease in mild cognitive impairment patients with discordant CSF/PET amyloid-β results ahead of anti-amyloid treatment. Read our news story #CTAD24

#CTAD24: Two real-world studies from the US characterize their experience of lecanemab use in patients with Alzheimer’s disease, finding it to be in line with ‘on label’ use

The AD and Related Disorders Therapeutic Workgroup has created appropriate use recommendations for donanemab to help guide clinicians when identifying patients suitable for treatment #CTAD24 Read our news story here

#CTAD24: TRAILBLAZER-ALZ 6 study findings suggest a moderation to donanemab dosing could help reduce ARIA-E risk. Read the news story here

Will you be at CTAD 2024? If not, we've got you covered. Keep an eye out for news articles and expert interviews posted live from the congress.

RT @SpringerNature: For the October edition of #BooksInspired, we’re once again excited to roll out the red carpet for a selection of title…

Join Dr Jennifer Green and learn how CGM improves glycaemic control in type 2 diabetes, reduces hospitalizations, and enhances glucose management in hospitals. Plus, get a glimpse into future CGM devices! Watch here #Diabetescare #CGM #Glucose #Diabetes

Case study Dr Sameera Auckburally authors the latest expert case study guiding us through the diagnosis and treatment of an 8-hour-old infant with persistent hypoglycaemia. Read the case study here